Hofmann's Sacred Drug Hypothesis: Mystical Experience as Mechanism

“Hofmann argued LSD works by providing access to mystical experience. The clinical literature now confirms mystical experience quality predicts therapeutic outcomes better than drug dose alone.”

The claim: Hofmann argued throughout My Problem Child that LSD's therapeutic benefit derives from its ability to produce genuine mystical experience, a direct encounter with what he called the sacred, and that the drug should be understood as a 'sacred drug' rather than merely a pharmacological agent.

The evidence: The Mystical Experience Questionnaire (MEQ30), derived from philosopher Walter Stace's phenomenological analysis, now measures mystical experience reliably in clinical trial participants. Multiple studies have found that MEQ30 score predicts therapeutic outcomes across conditions, depression, alcohol use disorder, end-of-life anxiety, better than drug dose alone.

Griffiths et al. (Johns Hopkins, 2006) established this with psilocybin in healthy volunteers. Barrett and Griffiths (2018) confirmed that complete mystical experiences (MEQ30 score above 60%) are specifically associated with sustained therapeutic benefit. The industry Phase 3 trials (the first, June 2025; the second, February 2026) produced data consistent with this: 25% of participants showing clinically meaningful depression reduction maintained that response through 26 weeks, and the quality of the experience, not only the dose, is a key predictor.

Hofmann's insistence on the word 'sacred' was not religious in the denominational sense, it was a claim that the compound acts through a specific quality of consciousness, not through receptor pharmacology alone. The MEQ30 is measuring this claim. It is confirmed.

Verdict: Was right. The mechanism Hofmann proposed, therapeutic benefit through mystical experience quality, is now the primary mechanistic hypothesis in clinical psychedelic research. The word 'sacred' has been replaced by 'mystical experience score,' but the underlying claim is the same.

Sources

• Hofmann, LSD: My Problem Child (1979)
• Griffiths et al., Psychopharmacology (2006)
• Barrett & Griffiths, Curr Top Behav Neurosci (2018)
• Industry Phase 3 psilocybin trial results (2025-2026)